TWA
LXRX icon

Talisman Wealth Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Talisman Wealth Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.6K Buy
+10,000
New +$14.5K 0.01% 101

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Talisman Wealth Advisors's LXRX Position: Q1 2026 in Review

Talisman Wealth Advisors opened a new position in Lexicon Pharmaceuticals (LXRX) in Q1 2026: 10,000 shares worth $15.6K. The stake represents 0.01% of the portfolio and ranks #101 among its holdings.

136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Talisman Wealth Advisors held 10,000 shares of Lexicon Pharmaceuticals worth $15.6K as of Q1 2026.
  • Lexicon Pharmaceuticals was a new Talisman Wealth Advisors position in Q1 2026.
  • Lexicon Pharmaceuticals made up 0.01% of Talisman Wealth Advisors's portfolio in Q1 2026, its #101 holding.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Talisman Wealth Advisors's 13F filing for Q1 2026, filed 15 May 2026.